Palvella Therapeutics (PVLA) Operating Income (2013 - 2026)
Palvella Therapeutics (PVLA) reported Operating Income of -$14.9 million for Q1 2026, down 88.73% year-over-year from -$131.8 million in Q1 2025, and down 180.13% quarter-over-quarter from $18.5 million in Q4 2025.
Palvella Therapeutics (PVLA) Operating Income (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 14 years of Operating Income data on file, last reported at -$14.9 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$14.9 million, down 88.73% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.7 million (up 22.09% YoY), and the FY2025 annual result was -$8.8 million, up 37.85% from the prior year.
- Operating Income declined to -$14.9 million in Q1 2026 per PVLA's latest filing, from $18.5 million in the prior quarter.
- Over five years, Operating Income peaked at $18.5 million in Q4 2025 and troughed at -$15.5 million in Q1 2023.
- A 5-year average of -$5.1 million and a median of -$7.7 million in 2022 frame the typical range for Operating Income.
- On a YoY basis, Operating Income climbed as much as 524.6% in 2025 and fell as far as 347.47% in 2025.
- A 5-year view of Operating Income shows it stood at -$12.2 million in 2022, then soared by 210.01% to $13.4 million in 2023, then slumped by 132.62% to -$4.4 million in 2024, then soared by 524.6% to $18.5 million in 2025, then tumbled by 180.13% to -$14.9 million in 2026.
- Business Quant data shows PVLA's Operating Income at -$14.9 million in Q1 2026, $18.5 million in Q4 2025, and -$10.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | -14.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.86 Mn |
| Dec 31, 2025 | 18.54 Mn |
| Sep 30, 2025 | -10.18 Mn |
| Jun 30, 2025 | -9.25 Mn |
| Mar 31, 2025 | -7.87 Mn |
| Dec 31, 2024 | -4.37 Mn |
| Sep 30, 2024 | -5.06 Mn |
| Jun 30, 2024 | -2.91 Mn |
| Mar 31, 2024 | -1.76 Mn |
| Dec 31, 2023 | 13.39 Mn |
| Sep 30, 2023 | -11.81 Mn |
| Jun 30, 2023 | 2.06 Mn |
| Mar 31, 2023 | -15.51 Mn |
| Sep 30, 2022 | -12.17 Mn |
| Jun 30, 2022 | -12.33 Mn |
| Mar 31, 2022 | -7.46 Mn |
| Dec 31, 2021 | -11.00 Mn |
| Sep 30, 2021 | -19.01 Mn |
| Jun 30, 2021 | -16.76 Mn |
| Mar 31, 2021 | -5.06 Mn |